Enorama Pharma ABOSTO:ERMA 29 OCF Yield % is -213.80 as of Jul. 04, 2026. GuruFocus rates OSTO:ERMA with a GF Score™ of 29/100 and a GF Value™ of kr0.41 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Enorama Pharma AB ranks worse than 99.21% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Enorama Pharma AB OCF Yield % Related Terms
Enorama Pharma AB OCF Yield % Historical Data
* Premium members only.
The historical data trend for Enorama Pharma AB's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:ERMA vs ZTS, UTHR, VTRS: OCF Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Enorama Pharma AB's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Enorama Pharma AB OCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Enorama Pharma AB's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Enorama Pharma AB's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enorama Pharma AB (OSTO:ERMA) has a OCF Yield % of -213.80 as of Jul. 04, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Enorama Pharma AB and its competitors. According to the industry distribution chart, Enorama Pharma AB ranks #999 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 99.2%.
Is Enorama Pharma AB's OCF Yield % too high?
Enorama Pharma AB's current OCF Yield % is -213.80. Based on the distribution chart, Enorama Pharma AB ranks #999 out of 1007 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Enorama Pharma AB has a GF Score™ of 29/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Enorama Pharma AB's OCF Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Enorama Pharma AB ranks #999 out of 1007 companies for OCF Yield %. This places Enorama Pharma AB in the lower half of its industry. The industry median OCF Yield % is 3.43. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Drug Manufacturers company?
The median OCF Yield % among Drug Manufacturers companies is 3.43, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Enorama Pharma AB and its competitors. For the Drug Manufacturers industry, the median OCF Yield % is 3.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Enorama Pharma AB's current OCF Yield % is -213.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enorama Pharma AB stock overvalued right now?
Based on GuruFocus' analysis, Enorama Pharma AB (OSTO:ERMA) is currently considered Modestly Undervalued. The stock's GF Value™ is kr0.41, compared to a current price of kr0.30 — trading 27.8% below its estimated fair value. The current OCF Yield % is -213.80. Enorama Pharma AB's overall GF Score™ is 29/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Enorama Pharma AB (OSTO:ERMA), the current OCF Yield % is -213.80 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Enorama Pharma AB (OSTO:ERMA) Overvalued in 2026?
Based on GuruFocus' analysis, Enorama Pharma AB stock appears to be undervalued.
The current stock price of kr0.30 is trading 27.8% below its estimated GF Value™ of kr0.41.
GuruFocus considers Enorama Pharma AB to be Modestly Undervalued.
Key valuation signals for OSTO:ERMA:
OCF Yield %: -213.80
GF Value™: kr0.41 vs. price of kr0.30 (27.8% below fair value)
No single metric tells the full story. See the OSTO:ERMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Enorama Pharma AB is a pharmaceutical company that focuses on consumer-friendly medicated chewing gum containing generic substances. It provides medicated gums containing generic pharmaceutical substances, developed through its ChewMed technology platform.
29GF Score
Get the complete analysis for OSTO:ERMA
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:ERMA has been successfully added to your 
